FOXNews.com: Galenica's kidney drug meets endpoint in trial

FOXNews.com FOX News Network - We Report. You Decide. // via fulltextrssfeed.com

Galenica's kidney drug meets endpoint in trial Jul 9th 2012, 11:50 Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory filings in the United States, Europe and Switzerland. Results of the six-month phase III study found that maintenance doses of PA21 were superior in sustaining the phosphate-lowering effect in patients with chronic kidney disease who are on dialysis versus a PA21 inactive low dose. The company plans to submit PA21, which it developed in collaboration with Fresenius Medical Care, for regulatory approval in the fourth-quarter of 2012.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions